{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:50:28Z","timestamp":1791575428678,"version":"4.3.4"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"41","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,9]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Type 2 diabetes mellitus (T2DM) complicated by chronic kidney disease (CKD) is associated with persistent hyperglycemia, progressive renal impairment, systemic inflammation, and an increased risk of adverse clinical outcomes. Sodium\u2013glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists have shown metabolic and cardiorenal benefits, but clinical evidence regarding their combined use in patients with T2DM and CKD remains limited. This retrospective observational study included 126 patients with T2DM complicated by CKD who were treated at our hospital between March 2023 and July 2024. Patients were identified through a review of electronic medical records and the application of predefined eligibility criteria. Treatment groups reflected the actual regimen documented in the medical record rather than random allocation. The final analytic cohort comprised 42 patients in each group; the equal group size reflected the eligible records with complete baseline and 8-week follow-up data available in each treatment category during the study period rather than a prospective 1:1:1 enrollment target. The treatment duration was 8 weeks. Glycemic indices, renal function-related parameters, inflammatory markers, clinical response, and recorded adverse events were compared among the 3 groups. After 8 weeks of treatment, fasting plasma glucose, 2-hour postprandial plasma glucose, hemoglobin A1c, blood urea nitrogen, serum creatinine, 24-hour urinary protein, erythrocyte sedimentation rate, interleukin-6, and high-sensitivity C-reactive protein were significantly reduced in all 3 groups compared with baseline. The combination group showed greater short-term reductions in glycemic indices, renal function-related parameters, and inflammatory markers than either monotherapy group. The overall clinical response rate was significantly higher in the combination group than in the dapagliflozin or semaglutide group. In patients with T2DM complicated by CKD, semaglutide combined with dapagliflozin was associated with greater short-term improvements in glycemic control, inflammatory markers, and renal function-related indicators, as well as a higher exploratory clinical response rate, than either monotherapy. No increase in recorded adverse events was detected during 8 weeks of treatment. Because of the retrospective design, modest sample size, and short observation period, these findings should not be interpreted as demonstrating definitive long-term renal benefit or equivalent long-term safety. Further large-scale prospective studies with standardized renal outcomes are required.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000051019","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:01:06Z","timestamp":1791572466000},"page":"e51019","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Short-term clinical efficacy and recorded adverse events of semaglutide combined with dapagliflozin in patients with type 2 diabetes mellitus and chronic kidney disease"],"prefix":"10.1097","volume":"105","author":[{"given":"Cheng","family":"Gong","sequence":"first","affiliation":[{"name":"Department of Geriatric Medicine, Yangtze River Shipping General Hospital, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Yangtze River Shipping General Hospital, Hubei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8832-7089","authenticated-orcid":false,"given":"Qin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Yangtze River Shipping General Hospital, Hubei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261009","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.2337\/dci22-0027","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO).","volume":"45","author":"de Boer","year":"2022","journal-title":"Diabetes Care"},{"key":"R2-20261009","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.kint.2022.08.012","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO).","volume":"102","author":"de Boer","year":"2022","journal-title":"Kidney Int"},{"key":"R3-20261009","doi-asserted-by":"crossref","first-page":"2636407","DOI":"10.1080\/0886022X.2026.2636407","article-title":"Dapagliflozin improves hemoglobin and anemia in chronic kidney disease: a systematic review and meta-analysis.","volume":"48","author":"Irvania","year":"2026","journal-title":"Ren Fail"},{"key":"R4-20261009","doi-asserted-by":"crossref","first-page":"381","DOI":"10.7326\/M22-2904","article-title":"Diabetes management in chronic kidney disease: synopsis of the KDIGO 2022 clinical practice guideline update.","volume":"176","author":"Navaneethan","year":"2023","journal-title":"Ann Intern Med"},{"key":"R5-20261009","doi-asserted-by":"crossref","first-page":"1631053","DOI":"10.3389\/fmed.2025.1631053","article-title":"Diabetic kidney disease: from pathogenesis to multimodal therapy-current evidence and future directions.","volume":"12","author":"Zhang","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"R6-20261009","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1016\/j.apsb.2020.12.020","article-title":"Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management.","volume":"11","author":"Tang","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"R7-20261009","doi-asserted-by":"crossref","first-page":"1415879","DOI":"10.3389\/fphar.2024.1415879","article-title":"SGLT2i and GLP1-RA exert additive cardiorenal protection with a RAS blocker in uninephrectomized db\/db mice.","volume":"15","author":"Martos-Guillami","year":"2024","journal-title":"Front Pharmacol"},{"key":"R8-20261009","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1161\/CIRCULATIONAHA.120.050391","article-title":"Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF.","volume":"143","author":"Jhund","year":"2021","journal-title":"Circulation"},{"key":"R9-20261009","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes.","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"R10-20261009","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","article-title":"Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials.","volume":"13","author":"Badve","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R11-20261009","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2213-8587(24)00155-4","article-title":"Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials.","volume":"12","author":"Apperloo","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R12-20261009","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1161\/CIRCULATIONAHA.124.071689","article-title":"Cardiovascular, kidney, and safety outcomes with GLP-1 receptor agonists alone and in combination with SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis.","volume":"150","author":"Neuen","year":"2024","journal-title":"Circulation"},{"key":"R13-20261009","doi-asserted-by":"crossref","first-page":"771","DOI":"10.34067\/KID.0000000000000425","article-title":"SGLT2 inhibitors and kidney protection: mechanisms beyond tubuloglomerular feedback.","volume":"5","author":"Upadhyay","year":"2024","journal-title":"Kidney360"},{"key":"R14-20261009","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.","volume":"400","year":"2022","journal-title":"Lancet"},{"key":"R15-20261009","doi-asserted-by":"crossref","first-page":"1750615","DOI":"10.3389\/fendo.2026.1750615","article-title":"Efficacy and safety of novel antidiabetic drugs in patients with type 2 diabetes and chronic kidney disease: a network meta-analysis.","volume":"17","author":"Zhu","year":"2026","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R16-20261009","doi-asserted-by":"crossref","first-page":"1805015","DOI":"10.3389\/fendo.2026.1805015","article-title":"Real-world use of semaglutide in patients with type 2 diabetes and end-stage renal disease: a multicenter retrospective cohort study.","volume":"17","author":"Alkhezi","year":"2026","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R17-20261009","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1038\/s41591-024-03133-0","article-title":"Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial.","volume":"30","author":"Mann","year":"2024","journal-title":"Nat Med"},{"key":"R18-20261009","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic kidney disease: challenges, progress, and possibilities.","volume":"12","author":"Alicic","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"R19-20261009","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12933-022-01585-7","article-title":"Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials.","volume":"21","author":"Mosenzon","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"R20-20261009","doi-asserted-by":"crossref","first-page":"20420188231222367","DOI":"10.1177\/20420188231222367","article-title":"Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications.","volume":"15","author":"Alharbi","year":"2024","journal-title":"Ther Adv Endocrinol Metab"},{"key":"R21-20261009","doi-asserted-by":"crossref","first-page":"101248","DOI":"10.1016\/j.xkme.2026.101248","article-title":"Sodium-glucose cotransporter-2 inhibitors and acute kidney injury risk: a systematic review and meta-analysis of randomized trials.","volume":"8","author":"Chiang","year":"2026","journal-title":"Kidney Med"},{"key":"R22-20261009","doi-asserted-by":"crossref","first-page":"e1002983","DOI":"10.1371\/journal.pmed.1002983","article-title":"Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: a systematic review and meta-analysis.","volume":"16","author":"Menne","year":"2019","journal-title":"PLoS Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000051019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:01:09Z","timestamp":1791572469000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000051019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":22,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000051019","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]},"assertion":[{"value":"2026-05-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-18","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}